Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
OwnerWayne P. Francoinventor
Life of this patent
Estimating the term…
Abstract
Acute and chronic heart disease is treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The progress of treatment is continuously monitored by echo-cardiogram with growth factor treatment and/or stem cell administration adjusted according to the results of the echo-cardiogram or clinical status of the patient. Heart disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.
Claims31
1-36. (canceled)
A method for the systemic, multi-tiered treatment of acute or chronic cardiomyopathy by delivering a formulation comprising one or more therapeutic growth factor proteins together with adult stem cells, the method comprising the steps of:
- a) selecting a patient displaying symptoms of acute or chronic cardiomyopathy;
- b) administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation into the endocardium via a catheter comprising:
- 1) a growth factor protein selected from the group consisting of FGF-1 and FGF-2, and mixtures thereof;
- and
- 2) a growth factor protein selected from the group consisting of VEGF, VEGF-A, VEGF-B, VEGF-165, and PIGF, and mixtures thereof;
- c) following said administration of a first therapeutic growth factor protein formulation, administrating of at least one dose of an effective amount of adult stem cells into the endocardium via a catheter;
- d) monitoring the effectiveness of administration of adult stem cells by echo-cardiogram and/or other clinical indicators;
- e) determining, based on monitoring the effectiveness of stem cell treatment by echo-cardiogram and/or other clinical indicators, whether an additional dose of stem cells is indicated or whether an additional dose of growth factor protein is indicated;
- f) depending on the results of the step e), administering a second dose of an effective amount of adult stem cells and/or growth factor proteins via a catheter into the endocardium;
- and
- if indicated, repeating steps b) through e) until there is a clinical indication of amelioration of the symptoms of acute or chronic heart disease in the patient, or until there is contraindication to continued treatment.
A method for the systemic, multi-tiered treatment of acute or chronic cardiomyopathy by delivering a formulation comprising one or more therapeutic growth factor proteins together with adult stem cells, the method comprising the steps of:
- a) selecting a patient displaying symptoms of acute or chronic cardiomyopathy;
- b) administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation into the myocardium via a catheter comprising:
- 1) a growth factor protein selected from the group consisting of FGF-1 and FGF-2, and mixtures thereof;
- and
- 2) a growth factor protein selected from the group consisting of VEGF, VEGF-A, VEGF-B, VEGF-165, and PIGF, and mixtures thereof;
- c) following said administration of a first therapeutic growth factor protein formulation, administrating of at least one dose of an effective amount of adult stem cells into the myocardium via a catheter;
- d) monitoring the effectiveness of administration of adult stem cells by echo-cardiogram and/or other clinical indicators;
- e) determining, based on monitoring the effectiveness of stem cell treatment by echo-cardiogram and/or other clinical indicators, whether an additional dose of stem cells is indicated or whether an additional dose of growth factor protein is indicated;
- f) depending on the results of the step e), administering a second dose of an effective amount of adult stem cells and/or growth factor proteins via a catheter into the myocardium;
- and
- if indicated, repeating steps b) through e) until there is a clinical indication of amelioration of the symptoms of acute or chronic heart disease in the patient, or until there is contraindication to continued treatment.
A method for the systemic, multi-tiered treatment of acute or chronic cardiomyopathy by delivering a formulation comprising one or more therapeutic growth factor proteins together with adult stem cells, the method comprising the steps of:
- a) selecting a patient displaying symptoms of acute or chronic cardiomyopathy;
- b) administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation into the coronary arteries via a catheter comprising:
- 1) a growth factor protein selected from the group consisting of FGF-1 and FGF-2, and mixtures thereof;
- and
- 2) a growth factor protein selected from the group consisting of VEGF, VEGF-A, VEGF-B, VEGF-165, and PIGF, and mixtures thereof;
- c) following said administration of a first therapeutic growth factor protein formulation, administrating of at least one dose of an effective amount of adult stem cells into the coronary arteries via a catheter;
- d) monitoring the effectiveness of administration of adult stem cells by echo-cardiogram and/or other clinical indicators;
- e) determining, based on monitoring the effectiveness of stem cell treatment by echo-cardiogram and/or other clinical indicators, whether an additional dose of stem cells is indicated or whether an additional dose of growth factor protein is indicated;
- f) depending on the results of the step e), administering a second dose of an effective amount of adult stem cells and/or growth factor proteins via a catheter into the coronary arteries;
- and
- if indicated, repeating steps b) through e) until there is a clinical indication of amelioration of the symptoms of acute or chronic heart disease in the patient, or until there is contraindication to continued treatment.
Dependencies are inferred from the claim text.